Covington Represents Elanco in Divestitures of Pet Care Products

Covington Represents Elanco in Divestitures of Pet Care Products

January 13, 2020

WASHINGTON—Covington represented Elanco Animal Health in connection with an agreement with Dechra Pharmaceuticals to divest Osurnia® for $135 million in an all-cash deal. Covington also represented Elanco in an agreement to divest the U.S. rights and related assets for Capstar® to PetIQ, Inc., for $95 million in an all-cash deal.

Elanco is a global animal health company that develops products and knowledge services to prevent and treat disease in animals and pets in more than 90 countries. Osurnia® is a treatment for otitis externa in dogs. Capstar® is an oral tablet that kills fleas in dogs and cats.

The Covington team included Michael Riella, Catherine Dargan, Lauren Visek, and Andrew Barna.